Hodgkin's Lymphoma Treatment Market Report 2026

The hodgkin's lymphoma treatment market size has grown strongly in recent years. It will grow from $3.56 billion in 2025 to $3.83 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing incidence of hodgkin's lymphoma, growing awareness and early diagnosis, rising adoption of chemotherapy and radiation therapy, expansion of oncology healthcare infrastructure, increasing government funding for cancer research.

The hodgkin's lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $5.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rising adoption of immunotherapy and targeted therapies, growing availability of stem cell transplantation, increasing patient preference for personalized treatments, expansion of cancer centers in emerging markets, rising insurance coverage and reimbursement support. Major trends in the forecast period include technology advancements in diagnostic imaging, innovations in immunotherapy and targeted therapies, developments in minimally invasive treatment options, research and developments in stem cell transplantation, integration of digital health and telemedicine in follow-up care.

The rising incidence of Hodgkin’s lymphoma is expected to drive the growth of the Hodgkin’s lymphoma treatment market in the coming years. This cancer of the lymphatic system is characterized by abnormal Reed-Sternberg cells in the lymph nodes, primarily affecting B‑lymphocytes and often presenting with painless swollen glands, fever, night sweats, and weight loss. The increasing cases are linked to greater exposure to risk factors such as smoking, obesity, hypertension, and changing socioeconomic conditions in many regions. Treatments, including chemotherapy, radiation, and immunotherapy, help manage the disease by targeting and eliminating malignant lymphocytes, improving patient outcomes through reduced disease progression, remission, and higher survival rates. For instance, in October 2025, the American Cancer Society estimated around 8,720 new cases of Hodgkin’s lymphoma in the United States, including 4,840 males and 3,880 females, with approximately 1,150 deaths, comprising 720 males and 430 females. Thus, the growing incidence of Hodgkin’s lymphoma is fueling the expansion of the treatment market.

Major companies in the Hodgkin’s lymphoma treatment sector are concentrating on developing advanced therapies, such as front‑line targeted combination treatments, to enhance treatment efficacy, minimize treatment-related side effects, and expand first-line options for patients with advanced-stage disease. Front-line targeted combination therapies involve administering two or more precision medicines together as an initial treatment to target multiple disease-driving mechanisms simultaneously, improving response rates and delaying resistance in newly diagnosed patients. For example, in June 2025, Takeda, a pharmaceutical company based in Japan, received European Commission approval for ADCETRIS in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (ECADD) for adults with newly diagnosed Stage IIb with risk factors, Stage III, or Stage IV Hodgkin lymphoma, based on Phase 3 HD21 trial results demonstrating superior safety and non-inferior progression-free survival compared with standard eBEACOPP chemotherapy. This front-line targeted combination therapy incorporates a targeted ADC backbone, a chemotherapy-optimized regimen designed to reduce acute toxicity, and broadened indications for frontline treatment, marking a notable advancement in Hodgkin’s lymphoma care.

In March 2023, Pfizer Inc., a US-based global biopharmaceutical company, acquired Seagen Inc. for approximately $43 billion. Through this acquisition, Pfizer intends to strengthen its Hodgkin’s lymphoma treatment portfolio by incorporating Seagen’s antibody-drug conjugate technology and marketed oncology medicines, including ADCETRIS (brentuximab vedotin), which is indicated for classical Hodgkin’s lymphoma. This move enhances Pfizer’s targeted oncology capabilities and broadens treatment options for hematologic malignancies. Seagen Inc. is a US-based biotechnology company focused on developing ADCETRIS (brentuximab vedotin), approved for the treatment of specific forms of Hodgkin lymphoma.

Major companies operating in the hodgkin's lymphoma treatment market are F. Hoffmann‑La Roche Ltd., Merck & Co. Inc., Pfizer Inc., Novartis AG, AstraZeneca plc, Bristol‑Myers Squibb Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Ono Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Seagen Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., BeiGene Ltd., Innovent Biologics Inc., HUTCHMED (China) Limited, Aurigene Discovery Technologies Limited, ADC Therapeutics SA, CStone Pharmaceuticals, Emcure Pharmaceuticals Ltd., Sorrento Therapeutics Inc.

North America was the largest region in the hodgkin's lymphoma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hodgkin's lymphoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hodgkin's lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have influenced the hodgkin's lymphoma treatment market by increasing the cost of imported chemotherapy drugs, advanced immunotherapy agents, and radiotherapy equipment. these impacts are particularly felt in regions like north america and europe where import dependency is higher. hospitals, specialty clinics, and cancer centers are the segments most affected due to higher procurement costs. despite these challenges, tariffs have encouraged local manufacturing and innovation in treatment solutions, potentially reducing long-term dependency on imports.

Hodgkin's lymphoma treatment involves medical strategies designed to manage and potentially cure Hodgkin's lymphoma, a cancer affecting the lymphatic system. It includes methods such as chemotherapy, radiation therapy, and targeted immunotherapy to destroy cancerous cells and halt disease progression. The goal of treatment is to achieve remission, increase survival chances, and improve the overall quality of life for patients.

The primary treatment types for Hodgkin’s lymphoma include chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Chemotherapy is a medical approach that uses drugs to kill or inhibit cancer cell growth. The disease types include classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Treatment stages include early-stage, advanced-stage, and relapsed conditions. Stem cell transplant options include autologous and allogeneic transplants. Key end users include hospitals, specialty clinics, cancer centers, ambulatory care centers, and home healthcare services.

The Hodgkin's lymphoma treatment market consists of sales of products such as chemotherapy drugs (e.g., doxorubicin, bleomycin, vinblastine, dacarbazine), targeted therapies (e.g., brentuximab vedotin), immunotherapy agents (e.g., checkpoint inhibitors), radiopharmaceuticals, monoclonal antibodies, combination therapy regimens, supportive care medications, and stem cell transplantation products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.